Business Standard

A COMMERCIAL FEATURE

What's this ?

Commercial Feature is a Business Standard Digital Marketing Initiative.

The Editorial/Content team at Business Standard has not contributed to writing or editing these articles.

For further information, please write to assist@bsmail.in

Glenmark licenses oncology products from US-based APC Therapeutics

Glenmark to have for exclusive rights to a small molecule, oncology compound based on APC biology

BS B2B Bureau  |  Mumbai 

Glenmark discovers new biologic drug for cancer treatment

has entered into a licensing agreement with Boston-based Inc, a biopharmaceutical company focused on building a portfolio of best-in-class immuno-(IO) therapies, for exclusive rights to a small molecule, compound based on Antigen Presenting Cell (APC) biology. The compound has the potential to be used as a monotherapy or in combination with approved therapies to address unmet needs in cancer treatment.

“This asset adds to our robust biologics pipeline of targeted IO therapies. The mechanism of action of APC biology is very intriguing and has the potential to be transformative in cancer treatment by triggering powerful immunologic responses to tumors that may lead to deeper and more durable responses to treatment,” said Kurt Stoeckli, president and chief scientific officer,

Under the terms of the agreement, will license the product from APC Therapeutics, and manage all clinical development including regulatory filings and commercialisation worldwide. will receive development milestones and sales royalty payments.

is an ideal partner to advance such an important scientific breakthrough treatment to patients with cancer. This partnership is strategically significant for as it validates and advances our commitment to bring the right immunotherapies to the right patient populations,” said Vinod Patel and Venkateshwar Reddy, the co-founders of

The global market is growing exponentially and projected to exceed $ 150 billion by 2020, according to figures from IMS Health. Driving this growth is the transition from short-term cytotoxic treatments towards precision medicines, most notably agents providing substantial increase in long-term survival. Because of these improvements, IO is one of the most promising and fastest growing areas of cancer treatment and research.

First Published: Wed, June 21 2017. 16:04 IST
RECOMMENDED FOR YOU

Glenmark licenses oncology products from US-based APC Therapeutics

Glenmark to have for exclusive rights to a small molecule, oncology compound based on APC biology

Glenmark to have for exclusive rights to a small molecule, oncology compound based on APC biology
has entered into a licensing agreement with Boston-based Inc, a biopharmaceutical company focused on building a portfolio of best-in-class immuno-(IO) therapies, for exclusive rights to a small molecule, compound based on Antigen Presenting Cell (APC) biology. The compound has the potential to be used as a monotherapy or in combination with approved therapies to address unmet needs in cancer treatment.

“This asset adds to our robust biologics pipeline of targeted IO therapies. The mechanism of action of APC biology is very intriguing and has the potential to be transformative in cancer treatment by triggering powerful immunologic responses to tumors that may lead to deeper and more durable responses to treatment,” said Kurt Stoeckli, president and chief scientific officer,

Under the terms of the agreement, will license the product from APC Therapeutics, and manage all clinical development including regulatory filings and commercialisation worldwide. will receive development milestones and sales royalty payments.

is an ideal partner to advance such an important scientific breakthrough treatment to patients with cancer. This partnership is strategically significant for as it validates and advances our commitment to bring the right immunotherapies to the right patient populations,” said Vinod Patel and Venkateshwar Reddy, the co-founders of

The global market is growing exponentially and projected to exceed $ 150 billion by 2020, according to figures from IMS Health. Driving this growth is the transition from short-term cytotoxic treatments towards precision medicines, most notably agents providing substantial increase in long-term survival. Because of these improvements, IO is one of the most promising and fastest growing areas of cancer treatment and research.

image
Business Standard
177 22

Glenmark licenses oncology products from US-based APC Therapeutics

Glenmark to have for exclusive rights to a small molecule, oncology compound based on APC biology

has entered into a licensing agreement with Boston-based Inc, a biopharmaceutical company focused on building a portfolio of best-in-class immuno-(IO) therapies, for exclusive rights to a small molecule, compound based on Antigen Presenting Cell (APC) biology. The compound has the potential to be used as a monotherapy or in combination with approved therapies to address unmet needs in cancer treatment.

“This asset adds to our robust biologics pipeline of targeted IO therapies. The mechanism of action of APC biology is very intriguing and has the potential to be transformative in cancer treatment by triggering powerful immunologic responses to tumors that may lead to deeper and more durable responses to treatment,” said Kurt Stoeckli, president and chief scientific officer,

Under the terms of the agreement, will license the product from APC Therapeutics, and manage all clinical development including regulatory filings and commercialisation worldwide. will receive development milestones and sales royalty payments.

is an ideal partner to advance such an important scientific breakthrough treatment to patients with cancer. This partnership is strategically significant for as it validates and advances our commitment to bring the right immunotherapies to the right patient populations,” said Vinod Patel and Venkateshwar Reddy, the co-founders of

The global market is growing exponentially and projected to exceed $ 150 billion by 2020, according to figures from IMS Health. Driving this growth is the transition from short-term cytotoxic treatments towards precision medicines, most notably agents providing substantial increase in long-term survival. Because of these improvements, IO is one of the most promising and fastest growing areas of cancer treatment and research.

image
Business Standard
177 22